CR8768A - Formulacion de irinotecan - Google Patents
Formulacion de irinotecanInfo
- Publication number
- CR8768A CR8768A CR8768A CR8768A CR8768A CR 8768 A CR8768 A CR 8768A CR 8768 A CR8768 A CR 8768A CR 8768 A CR8768 A CR 8768A CR 8768 A CR8768 A CR 8768A
- Authority
- CR
- Costa Rica
- Prior art keywords
- irinotecan
- mol
- preparation
- blood
- salt
- Prior art date
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 7
- 229960004768 irinotecan Drugs 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 4
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una preparacion de irinotecan que tiene irinotecan y/o una sal del mismo altamente portado por un portador vesicular cerrado, que muestra una retencion notablemente prolongada en la sangre, como se comparo con aquella de las preparaciones de liposoma de irinotecan convencionales y es capaz de estar presente en la sangre durante un periodo de tiempo prolongado. Se proporciona una preparacion de irinotecan que comprende vesiculas cerradas formadas de una membrana de lipido en donde el irinotecan y/o una sal del mismo se sellan en una concentracion de al menos 0.07 mol/mol (mol de medicina/mol de lipidos totales de la membrana). La preparacion de irinotecan preferiblemente tiene un gradiente ionico entre una fase acuosa interna y una fase acuosa externa dentro de las vesiculas cerradas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004163742 | 2004-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8768A true CR8768A (es) | 2007-08-28 |
Family
ID=35462721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8768A CR8768A (es) | 2004-06-01 | 2006-11-23 | Formulacion de irinotecan |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7846473B2 (es) |
| EP (1) | EP1752150B1 (es) |
| JP (1) | JP4885715B2 (es) |
| KR (1) | KR100889139B1 (es) |
| CN (1) | CN1960729B (es) |
| AP (1) | AP2255A (es) |
| AR (1) | AR049137A1 (es) |
| AU (1) | AU2005249314B2 (es) |
| BR (1) | BRPI0511753A (es) |
| CA (1) | CA2567857C (es) |
| CR (1) | CR8768A (es) |
| EA (1) | EA011612B1 (es) |
| EC (1) | ECSP067041A (es) |
| ES (1) | ES2594621T3 (es) |
| GE (1) | GEP20094620B (es) |
| IL (1) | IL179558A0 (es) |
| MX (1) | MXPA06013874A (es) |
| NO (1) | NO20066074L (es) |
| NZ (1) | NZ551748A (es) |
| TN (1) | TNSN06395A1 (es) |
| TW (1) | TWI362931B (es) |
| UA (1) | UA85099C2 (es) |
| WO (1) | WO2005117878A1 (es) |
| ZA (1) | ZA200610204B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| US20090196917A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions |
| CA2724408A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
| WO2010058840A1 (ja) * | 2008-11-20 | 2010-05-27 | テルモ株式会社 | リポソームからの薬物放出手段および放出性評価法 |
| WO2011066684A1 (zh) * | 2009-12-03 | 2011-06-09 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
| CN103120645B (zh) * | 2009-12-03 | 2015-03-11 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
| US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| CA2850955C (en) | 2011-11-03 | 2019-11-19 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| KR101842279B1 (ko) * | 2012-03-29 | 2018-03-26 | 우석대학교 산학협력단 | 이리노테칸의 안정성증진을 위한 주사제용 조성물 |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| AU2013312819A1 (en) * | 2012-09-04 | 2015-03-26 | Lauren Sciences Llc | Bolaamphiphilic compounds, compositions and uses thereof |
| EA023079B1 (ru) * | 2012-12-24 | 2016-04-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы иринотекана (варианты) |
| CN104906586A (zh) * | 2014-03-10 | 2015-09-16 | 中国科学院上海药物研究所 | 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用 |
| CN105796495B (zh) * | 2014-12-29 | 2020-10-23 | 南京绿叶制药有限公司 | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |
| CN105982857B (zh) * | 2015-02-09 | 2019-03-08 | 湖南科伦药物研究有限公司 | 一种盐酸伊立替康脂质体组合物及其制备方法 |
| ES2589320B2 (es) * | 2015-04-14 | 2017-06-01 | Universidad Politécnica de Madrid | Sistema de compartimentación de espacios con membranas enrollables |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| KR101646181B1 (ko) * | 2015-08-18 | 2016-08-05 | 한양대학교 에리카산학협력단 | 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물 |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| EP4647126A3 (en) | 2015-10-16 | 2026-02-11 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| CN110402163A (zh) * | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| CN109260155B (zh) | 2018-11-05 | 2021-04-06 | 杭州高田生物医药有限公司 | 伊立替康脂质体制剂及其制备与应用 |
| KR102185475B1 (ko) * | 2019-06-20 | 2020-12-02 | 대화제약 주식회사 | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 |
| CN115364218A (zh) * | 2021-05-21 | 2022-11-22 | 杭州高田生物医药有限公司 | 一种特定药脂比的药物组合物在抗肿瘤中的应用 |
| JP7724358B2 (ja) * | 2021-10-15 | 2025-08-15 | クンシャン シンユンダ バイオテック カンパニー， リミテッド | 抗腫瘍薬を含む組成物、並びにその調製方法及びその使用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| US6090407A (en) | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| KR100679906B1 (ko) * | 1998-09-16 | 2007-02-07 | 알자 코포레이션 | 리포솜-엔트랩된 토포이소머라제 억제제 |
| EP1190706B1 (en) * | 1999-06-25 | 2009-05-06 | Terumo Kabushiki Kaisha | Liposomes |
| JP2001064158A (ja) * | 1999-06-25 | 2001-03-13 | Terumo Corp | リポソーム |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| JP2004501955A (ja) * | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | リポソーム抗新生物薬剤およびその使用 |
| ES2272768T3 (es) | 2001-10-03 | 2007-05-01 | Celator Pharmaceuticals Inc | Composiciones para la administracion de combinaciones de farmacos. |
| AU2002331481B2 (en) | 2001-10-03 | 2008-04-24 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| ES2387886T3 (es) * | 2001-11-13 | 2012-10-03 | Celator Pharmaceuticals, Inc. | Composiciones que transportan lípidos con una mejor estabilidad sanguínea |
| AU2002340670A1 (en) * | 2001-11-13 | 2003-05-26 | Celator Technologies, Inc. | Lipid carrier compositions and methods for improved drug retention |
| EP1608338A1 (en) * | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| LT3173073T (lt) | 2004-05-03 | 2025-01-10 | Ipsen Biopharm Ltd. | Liposomos, skirtos vaistų pristatymui |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
-
2005
- 2005-05-31 KR KR1020067025238A patent/KR100889139B1/ko not_active Expired - Fee Related
- 2005-05-31 AU AU2005249314A patent/AU2005249314B2/en not_active Ceased
- 2005-05-31 UA UAA200614105A patent/UA85099C2/ru unknown
- 2005-05-31 CA CA002567857A patent/CA2567857C/en not_active Expired - Fee Related
- 2005-05-31 US US11/597,435 patent/US7846473B2/en active Active
- 2005-05-31 ES ES05745848.1T patent/ES2594621T3/es not_active Expired - Lifetime
- 2005-05-31 AP AP2006003837A patent/AP2255A/xx active
- 2005-05-31 EA EA200602246A patent/EA011612B1/ru not_active IP Right Cessation
- 2005-05-31 MX MXPA06013874A patent/MXPA06013874A/es not_active Application Discontinuation
- 2005-05-31 WO PCT/JP2005/009953 patent/WO2005117878A1/ja not_active Ceased
- 2005-05-31 BR BRPI0511753-4A patent/BRPI0511753A/pt not_active IP Right Cessation
- 2005-05-31 EP EP05745848.1A patent/EP1752150B1/en not_active Expired - Lifetime
- 2005-05-31 JP JP2006514098A patent/JP4885715B2/ja not_active Expired - Fee Related
- 2005-05-31 GE GEAP20059794A patent/GEP20094620B/en unknown
- 2005-05-31 CN CN2005800176008A patent/CN1960729B/zh not_active Expired - Fee Related
- 2005-05-31 NZ NZ551748A patent/NZ551748A/en unknown
- 2005-06-01 AR ARP050102246A patent/AR049137A1/es unknown
- 2005-06-01 TW TW094118012A patent/TWI362931B/zh not_active IP Right Cessation
-
2006
- 2006-11-23 CR CR8768A patent/CR8768A/es unknown
- 2006-11-23 IL IL179558A patent/IL179558A0/en unknown
- 2006-11-29 EC EC2006007041A patent/ECSP067041A/es unknown
- 2006-11-30 TN TNP2006000395A patent/TNSN06395A1/en unknown
- 2006-12-06 ZA ZA200610204A patent/ZA200610204B/xx unknown
- 2006-12-29 NO NO20066074A patent/NO20066074L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8768A (es) | Formulacion de irinotecan | |
| ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
| KR920700679A (ko) | 비(nasal) 전달용 지질부형제와 그 사용법 | |
| BR0316402A (pt) | vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica | |
| AR068323A1 (es) | Compuestos del acido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1'-h,3h-espiro[1-benzofuran-2,4'-piperidin]-1' -il)-2-hidroxipropil]oxi}4-[(metilamino)carbonil]fenoxi}-2-metilpropanoico, composiciones farmaceuticas que los contienen, metodo de preparacion y usos de los mismos en afecciones respiratorias | |
| CU23980B1 (es) | Formulación liposomal y proceso para la preparación del mismo | |
| NZ504017A (en) | Preparation of gatifloxacin and disodium edetate | |
| MX2010006436A (es) | Derivados peptidos mimeticos de eritropoyetina y sus sales farmaceuticas, su preparacion y usos. | |
| ES2053678T3 (es) | Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular. | |
| ECSP088962A (es) | Nuevos herbicidas | |
| AR061024A1 (es) | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. | |
| HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
| BR112014010590A2 (pt) | 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose | |
| ES2303114T3 (es) | Metodo para cargar medicamentos en liposomas. | |
| ES2864667T3 (es) | Péptidos diseñados para la modulación de la barrera de unión estrecha | |
| ES2482107T3 (es) | Solución para la diálisis peritoneal | |
| ECSP066663A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
| PE20130064A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
| BRPI0115076B8 (pt) | preparação farmacêutica, sua aplicação farmacêutica, bem como processo para preparação da mesma | |
| PE20060484A1 (es) | Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina | |
| BRPI0606119A2 (pt) | preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis | |
| ES2244591T3 (es) | Composicion farmaceutica de diclofenac basada en vitamina e, papaina y hialuronidasa. | |
| AR048138A1 (es) | Formulacion farmaceutica de liberacion controlada | |
| MX2021001820A (es) | Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos. | |
| RU2015146972A (ru) | Аптечка для оказания первой, скорой и экстренной медицинской помощи пораженным цианидами |